The HIV PrEP and Microbicides Pipeline
Pipeline • 2018July 2018 by Jeremiah Johnson Since 2011, HIV prevention has undergone a true revolution. With three major studies (HPTN 052, PARTNER, and Opposites Attract) now showing zero new infections linked to an HIV positive person who has successfully suppressed their virus through antiretroviral treatment, it is now apparent that being “undetectable” means that a person…
Preventive Technologies: Antiretroviral and Vaccine Development
Pipeline • 2017July 2017 By Jeremiah Johnson and Richard Jefferys INTRODUCTION Recent advances in the research, development, and implementation of biomedical HIV prevention—primarily in the form of treatment as prevention (TasP) and tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC) as pre-exposure prophylaxis (PrEP)—already appear to be bearing fruit in addressing complex HIV epidemics. At this year’s Conference on…
Preventive Technologies: Antiretroviral and Vaccine Development
Pipeline PDF • 2017Preventive Technologies: Antiretroviral and Vaccine Development
Research Toward a Cure and Immune-Based Therapies
Pipeline • 2017July 2017 By Richard Jefferys INTRODUCTION The research effort to cure HIV infection has continued to expand over the past year. The National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) announced the funding of six new Martin Delaney Collaboratorys (up from three funded previously), which are collaborative…
The TB Prevention Pipeline
Pipeline • 2017July 2017 By Mike Frick INTRODUCTION One of the tuberculosis (TB) field’s most often voiced truisms has been that one-third of humanity is infected with Mycobacterium tuberculosis (MTB), the causative agent of TB disease. This estimate is invoked so frequently that it has become conventional wisdom and outgrown the need for a citation. A new…
HCV Pipeline: DAAs and Diagnostics in the Pangenotypic Era
Pipeline • 2017July 2017 By Annette Gaudino INTRODUCTION The continued development of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) has brought both multigenotypic and pangenotypic regimens to market, with more on the horizon. These simpler-to- prescribe regimens potentially eliminate the need for genotype testing, have shown improved efficacy in previously difficult-to-treat patients, and hold the promise…
Introduction and Executive Summary
Pipeline • 2017July 2017 By Mark Harrington INTRODUCTION This year marks the 30th year since the U.S. Food and Drug Administration (FDA) granted a license for Burroughs-Wellcome to market AZT (zidovudine, Retrovir), the first approved drug to treat HIV infection, at the then-unprecedented price of $10,000 per year. The hope instigated by this apparent medical progress mixed…
Lessons from History for Today’s HIV Response
TAGline • 2017Maintaining and expanding the accomplishments of the past depend on a fight for their survival and growth—now more than ever By Mark Harrington Today’s political situation with respect to the struggle to end HIV/AIDS, to treat all of those infected, and to reduce new transmission of the virus to zero, is facing new and unprecedented…
Preventive Technologies: Antiretroviral and Vaccine Development
Pipeline • 2016July 15, 2016 By Tim Horn and Richard Jefferys With the continued rollout and implementation of global, national, and regional HIV incidence targets and timelines, one thing has become abundantly clear: reducing HIV rates below endemic and epidemic levels in all vulnerable populations and subpopulations everywhere in the world will require not only a monumental…
The Tuberculosis Prevention Pipeline
Pipeline • 2016July 15, 2016 By Mike Frick After decades of receiving short shrift from most national TB programs and international organizations, tuberculosis (TB) prevention is finally coming into the mainstream. In 2015, the World Health Organization (WHO) published its first-ever Guidelines on the Management of Latent Tuberculosis Infection.1 The launch of these guidelines has awakened countries…